BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 101,924 Shares of Eli Lilly and Company (NYSE:LLY)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 14.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 593,202 shares of the company's stock after selling 101,924 shares during the quarter. Eli Lilly and Company makes up about 1.3% of BNP PARIBAS ASSET MANAGEMENT Holding S.A.'s investment portfolio, making the stock its 7th biggest position. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.06% of Eli Lilly and Company worth $525,542,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Peterson Financial Group Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at about $27,000. MidAtlantic Capital Management Inc. bought a new position in Eli Lilly and Company in the 3rd quarter worth approximately $30,000. Lynx Investment Advisory bought a new position in Eli Lilly and Company in the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company in the 2nd quarter valued at $36,000. Finally, Morton Brown Family Wealth LLC increased its stake in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company's stock valued at $41,000 after buying an additional 15 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 3.2 %

Shares of NYSE:LLY opened at $753.41 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company's 50-day moving average price is $872.25 and its two-hundred day moving average price is $869.98. The stock has a market capitalization of $715.23 billion, a PE ratio of 81.45, a price-to-earnings-growth ratio of 2.76 and a beta of 0.43. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business's revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company's dividend payout ratio is presently 56.22%.

Analyst Ratings Changes

Several analysts have weighed in on the company. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an "overweight" rating in a report on Friday, August 9th. Truist Financial increased their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a "buy" rating in a research note on Thursday, October 10th. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 target price for the company. Finally, Bank of America dropped their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a "buy" rating on the stock in a research report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,007.94.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.